迈科康生物 迈科康生物

CN

We focus on the R&D and production of innovative vaccines and new adjuvants.

about

mAXVAX

We focus on the R&D and production of innovative vaccines and new adjuvants.

Maxvax Biotechnology was founded by Dr. Dexiang Chen in 2016 in China's south-western city of Chengdu. We are a global biopharmaceutical enterprise dedicated to the research, development, production and commercialization of innovative vaccines and new adjuvants.
More

Technology

& production

We provide customers with high-quality, safe
and innovative products.

Technology Platform

Maxvax has pioneered three technological platforms: recombinant protein, adjuvants, and mRNA, aimed at treating infectious diseases, cancer, and allergies.

Learn more

Technology
Platform

+

Pipeline Introduction

Utilizing our technology platforms, we have developed a diverse pipeline of prophylactic and therapeutic vaccines to combat global health burdens.

Learn more

Pipeline
Introduction

+

Production Capability

We have constructed over 200,000 sq ft of state-of-the-art R&D and manufacturing facilities to support our pipeline, enabling us to handle product development all the way to industrial scale manufacturing, all in-house.

Learn more...

Production
Capability

+

news

center

Maxvax Newsletters

  • 152024.07

    Breaking News | Maxvax has enrolled first human subject for Shingles vaccine Phase III clinical studies

    On July 13, 2024, Maxvax’s recombinant herpes zoster (Shingles) vaccine (CHO cell) finished the enrollment of its first human subject for Phase III clinical trial in China’s Henan Province, marking the launch of the vaccine’s Phase III clinical trial.

    more >
  • 012024.07

    Financing Progress | Maxvax Finishes C+ Funding

    Chengdu Maxvax Biotechnology LLC. recently announced the completion of its Series C+ financing round, raising over 300 million CNY.

    more >
  • 282024.06

    Breaking News | Maxvax’s Recombinant Respiratory Syncytial Virus Vaccine Approved for Clinical Study

    On June 28, 2024, Chengdu Maxvax Biotechnology LLC (hereinafter referred to as “Maxvax”) announced that its application for a clinical trial of a new vaccine - recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) - has been approved by China’s Center for Drug Evaluation (CDE).

    more >
See more

contact

mAXVAX

We are here if you have any questions and needs.

  • Contact Us

  • Opportunities

  • Branches